{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:48:37Z","timestamp":1791071317609,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.idc.2005.05.007","type":"journal-article","created":{"date-parts":[[2005,8,14]],"date-time":"2005-08-14T11:35:40Z","timestamp":1124019340000},"page":"603-615","source":"Crossref","is-referenced-by-count":31,"title":["Neonatal Candidiasis"],"prefix":"10.1016","volume":"19","author":[{"given":"P. Brian","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Pt 1","key":"10.1016\/j.idc.2005.05.007_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1542\/peds.110.2.285","article-title":"Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network","volume":"110","author":"Stoll","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib2","article-title":"Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality, and neuro-developmental outcomes at 18\u201322 months","author":"Benjamin","year":"2005","journal-title":"Pediatrics"},{"issue":"3 Pt 1","key":"10.1016\/j.idc.2005.05.007_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1542\/peds.112.3.543","article-title":"Empirical therapy for neonatal candidemia in very low birth weight infants","volume":"112","author":"Benjamin","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.jp.7211068","article-title":"Mortality following blood culture in premature infants: increased with gram-negative bacteremia and candidemia, but not gram-positive bacteremia","volume":"24","author":"Benjamin","year":"2004","journal-title":"J Perinatol"},{"issue":"3 Pt 1","key":"10.1016\/j.idc.2005.05.007_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.112.3.634","article-title":"Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques","volume":"112","author":"Benjamin","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00006454-200006000-00002","article-title":"Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome","volume":"19","author":"Friedman","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/00006454-200112000-00005","article-title":"Risk factors for Candida species colonization of neonatal intensive care unit patients","volume":"20","author":"Saiman","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00006454-200004000-00011","article-title":"Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group","volume":"19","author":"Saiman","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0195-6701(93)90057-7","article-title":"Selective decontamination with nystatin for control of a Candida outbreak in a neonatal intensive care unit","volume":"24","author":"Damjanovic","year":"1993","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.idc.2005.05.007_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-2007-999649","article-title":"Prophylactic oral nystatin and fungal infections in very-low-birthweight infants","volume":"5","author":"Sims","year":"1988","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.idc.2005.05.007_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006454-199209000-00008","article-title":"Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection","volume":"11","author":"Wainer","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00007691-200108000-00022","article-title":"Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?","volume":"23","author":"Koks","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.idc.2005.05.007_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2885.1997.tb00093.x","article-title":"Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid","volume":"20","author":"Vaden","year":"1997","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.idc.2005.05.007_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/clpt.1993.147","article-title":"Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life","volume":"54","author":"Saxen","year":"1993","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.idc.2005.05.007_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.39.1.1","article-title":"Resistance of Candida species to fluconazole","volume":"39","author":"Rex","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ajhp\/56.6.525","article-title":"The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy","volume":"56","author":"Lewis","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idc.2005.05.007_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1542\/peds.107.2.293","article-title":"Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant","volume":"107","author":"Kicklighter","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib18","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMoa010494","article-title":"Fluconazole prophylaxis against fungal colonization and infection in preterm infants","volume":"345","author":"Kaufman","year":"2001","journal-title":"N Engl J Med"},{"issue":"1 Pt 1","key":"10.1016\/j.idc.2005.05.007_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1542\/peds.105.1.14","article-title":"Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes","volume":"105","author":"Walsh-Sukys","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib20","first-page":"99","article-title":"Outcome of treatment of candidemia in children whose central catheters were removed or retained","volume":"8","author":"Eppes","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib21","unstructured":"Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among infants < 1000 g birthweight: risk factors, mortality, and neuro-developmental outcomes at 18\u201322 months. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004."},{"key":"10.1016\/j.idc.2005.05.007_bib22","first-page":"301A","article-title":"The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study","volume":"51","author":"Karlowicz","year":"2002","journal-title":"Pediatr Res"},{"key":"10.1016\/j.idc.2005.05.007_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00006454-199811000-00008","article-title":"Management of neonatal candidiasis. Neonatal Candidiasis Study Group","volume":"17","author":"Rowen","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib24","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3476(05)82674-5","article-title":"Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates","volume":"116","author":"Baley","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.idc.2005.05.007_bib25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children","volume":"155","author":"Starke","year":"1987","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2005.05.007_bib26","first-page":"240","article-title":"Therapeutic treatment of systemic candidiasis in newborns","volume":"3","author":"Serra","year":"1991","journal-title":"J Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-003-0993-4","article-title":"High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates","volume":"22","author":"Juster-Reicher","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2005.05.007_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1542\/peds.73.2.153","article-title":"Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity","volume":"73","author":"Baley","year":"1984","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.007_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/318473","article-title":"Candida lusitaniae: a cause of breakthrough fungemia in cancer patients","volume":"32","author":"Minari","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.007_bib31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/JCM.40.3.852-856.2002","article-title":"Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2005.05.007_bib32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10096-004-1210-9","article-title":"Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates","volume":"23","author":"Roilides","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2005.05.007_bib33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations","volume":"52","author":"Linder","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.42.4.767","article-title":"In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?","volume":"42","author":"Swenson","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00467-004-1463-7","article-title":"The longest use of liposomal amphotericin B and 5-fluorocytosine","volume":"19","author":"Biyikli","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.idc.2005.05.007_bib37","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1136\/fn.84.2.F131","article-title":"Amphotericin B lipid complex for neonatal invasive candidiasis","volume":"84","author":"Adler-Shohet","year":"2001","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.idc.2005.05.007_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00006454-199908000-00010","article-title":"Amphotericin B lipid complex in pediatric patients with invasive fungal infections","volume":"18","author":"Walsh","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-2003-40008","article-title":"Neonatal invasive candidiasis: a prospective multicenter study of 118 cases","volume":"20","author":"Lopez Sastre","year":"2003","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.idc.2005.05.007_bib40","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/00007611-197911000-00036","article-title":"Candida meningitis in the newborn","volume":"72","author":"Rao","year":"1979","journal-title":"South Med J"},{"key":"10.1016\/j.idc.2005.05.007_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","article-title":"Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis","volume":"6","author":"Smego","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.idc.2005.05.007_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2165\/00003495-200464090-00003","article-title":"Antifungals in systemic neonatal candidiasis","volume":"64","author":"Frattarelli","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.idc.2005.05.007_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3476(74)80134-4","article-title":"Leukocyte function in normal and infected neonates","volume":"85","author":"Anderson","year":"1974","journal-title":"J Pediatr"},{"key":"10.1016\/j.idc.2005.05.007_bib44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s004310050906","article-title":"Pharmacokinetics of oral fluconazole in premature infants","volume":"157","author":"Wenzl","year":"1998","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.idc.2005.05.007_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00006454-199612000-00011","article-title":"Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial","volume":"15","author":"Driessen","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF01974619","article-title":"Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents","volume":"13","author":"Fasano","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2005.05.007_bib47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00006454-199708000-00007","article-title":"Prospective study of fluconazole therapy in systemic neonatal fungal infection","volume":"16","author":"Wainer","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib48","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1128\/JCM.37.11.3735-3737.1999","article-title":"Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility","volume":"37","author":"Rowen","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2005.05.007_bib49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/46.2.338","article-title":"Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis","volume":"46","author":"Muller","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2005.05.007_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2005.05.007_bib52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib53","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/AAC.41.7.1612","article-title":"In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species","volume":"41","author":"Vazquez","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib54","unstructured":"Walsh TJ, Adamson PC, Seibel NL, et al, Pharmacokinetics of caspofungin in pediatric patients [abstract]. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 2002."},{"issue":"Suppl 1","key":"10.1016\/j.idc.2005.05.007_bib55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/mmy.38.s1.335.347","article-title":"New targets and delivery systems for antifungal therapy","volume":"38","author":"Walsh","year":"2000","journal-title":"Med Mycol"},{"key":"10.1016\/j.idc.2005.05.007_bib56","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.007_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.inf.0000078164.80233.14","article-title":"Retrospective study of the safety of caspofungin in immunocompromised pediatric patients","volume":"22","author":"Franklin","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.007_bib58","unstructured":"Towsend R, Bekersky I, Buell D, Seibel N. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients. Presented at Focus on Fungal Infections. Washington (DC), 2001."},{"key":"10.1016\/j.idc.2005.05.007_bib59","unstructured":"Heresi G, Gerstmann D, Blumer J, et al. A pharmacokinetic study of micafungin (FK463) in premature infants [abstract]. Presented at Pediatric Academic Society. Seattle, 2003."},{"key":"10.1016\/j.idc.2005.05.007_bib60","unstructured":"Benjamin DK, Driscoll T, Siebel N, et al, Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC), 2004."},{"key":"10.1016\/j.idc.2005.05.007_bib61","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/AAC.45.12.3322-3327.2001","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib62","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1128\/AAC.46.6.1857-1869.2002","article-title":"Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits","volume":"46","author":"Petraitis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2005.05.007_bib63","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552005000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552005000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T05:58:59Z","timestamp":1683179939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552005000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0891552005000437"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2005.05.007","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}